Ondine Announces Share Consolidation and Name Change


 
TIDMOBP 
 
Ondine Announces Share Consolidation and Name Change 
FOR:  ONDINE BIOPHARMA CORPORATION 
 
TSX, AIM SYMBOL:  OBP 
 
October 11, 2010 
 
Ondine Announces Share Consolidation and Name Change 
 
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 11, 2010) - Ondine Biopharma Corporation 
(TSX:OBP)(AIM:OBP) (the "Company") today announced that the Company has received Toronto Stock 
Exchange acceptance and will proceed with the consolidation of all of its issued and outstanding 
common shares on the basis of fifteen (15) "old" common shares for one (1) "new" common share (the 
"Consolidation") and the name change from "Ondine Biopharma Corporation" to "Ondine Biomedical Inc.". 
Fractional shares remaining after giving effect to the Consolidation will be cancelled, such that 
shareholdings of each shareholder will be rounded down to the nearest whole number of post- 
consolidation common shares. 
 
The shares of the Company will commence trading on the TSX and on the AIM Market of the London Stock 
Exchange on a consolidated basis under the new name "Ondine Biomedical Inc." at the opening of trading 
on Thursday, October 14, 2010. The CUSIP number for the Company's post-consolidation common shares is 
68234M106. The Company's trading symbol, OBP, will not change. 
 
About Ondine Biopharma Corporation 
 
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, 
fungal and viral infections. The Company is focused on developing leading edge products utilizing its 
patented light-activated technology, primarily for the Hospital Acquired Infection (HAI) market. 
Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and 
spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a 
research and development laboratory in Bothell, Washington, USA. For additional information, please 
visit the Company's website at: www.ondinebio.com. 
 
 
-30- 
 
FOR FURTHER INFORMATION PLEASE CONTACT: 
 
Ondine Biopharma Corporation 
Carolyn Cross 
Chairman and Chief Executive Officer 
(604) 669-0555 
ccross@ondinebiopharma.com 
www.ondinebio.com 
 
OR 
 
Canaccord Genuity Limited 
Nominated Adviser 
Ryan Gaffney 
+4420 7050 6500 
 
The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of 
this release. 
 
 
 
 
Ondine Biopharma Corporation

Ondine Biomed (LSE:OBP)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024